🚀Your JUMP on Today

Macro, Geopolitics, Expenditures, Trade Idea, Bonus Report  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

July 30, 2026   |   Read online *together with Option Pit “Show Me The Money Window” 10 Minutes Per Day. Same Time Daily. Goal Is Fast Wins On Just 2 Stocks ⇒ Free Training With Olivia Voz. Good morning, RagingBull fam! That was quite the session yesterday! The DOW was down 900 points when I was having lunch around noon! Today is a new day, so let’s get right to it! The U.S. stock market heads into today under pressure as investors digest a high-stakes Federal Reserve policy decision, critical geopolitical escalations in the Middle East, and a massive wave of Big Tech earnings. After enduring volatility that dragged down the blue-chip Dow Jones Industrial Average by hundreds of points, the market's focus has shifted entirely to structural economic data. This morning brings a crucial barrage of macroeconomic indicators, led by the first preliminary reading of Q2 GDP and the June Core PCE Deflator data. Traders are analyzing whether corporate profit growth can withstand a challenging landscape of sticky inflation, high borrowing costs, and aggressive market rotation ⭐Navigating the Macro Triggers: The final trading session of July is dominated by major policy adjustments and economic data releases that will shape asset allocations for the remainder of the quarter. Deconstructing the Fed's Move: The market is responding to the latest monetary policy verdict delivered by Federal Reserve Chairman Kevin Warsh. Heading into the announcement, futures markets factored in a nervous 30% to 35% chance of a surprise interest rate hike. This volatility stemmed from the Fed's updated, tight-lipped communication style and a determination to clamp down on sticky consumer inflation. Absorbing the Q2 Data Gauntlet: At 8:30 a.m. ET, the Bureau of Economic Analysis drops the first reading of Q2 GDP alongside Personal Income and Consumption numbers. Most importantly, the Core PCE Deflator—the Fed's preferred inflation metric—will either validate a potential rate pause or fuel anxiety that higher-for-longer rates are locked in. ⭐Managing Geopolitical and Commodity Shocks: Renewed hostilities in the Middle East have broken a brief diplomatic lull, introducing a sharp risk-off sentiment across global exchanges. Mitigating the Energy Spike: Following surprise Iranian ballistic missile attacks aimed at U.S. forces—and a subsequent joint U.S.-Saudi counter-strike against regional militias in Iraq—energy markets have re-accelerated. Global benchmark Brent crude futures jumped over 6% back above $89 per barrel. Tracking Inflationary Drag: The sudden commodity spike threatens to reverse recent cooling in consumer prices. Long-term borrowing benchmarks, such as the 30-year U.S. Treasury yield, remain elevated above 5%, choking corporate debt markets and placing severe stress on growth equity valuations. ⭐Auditing Big Tech Capital Expenditures: Equity leadership continues to undergo a massive structural rotation away from high-flying semiconductor names and toward defensive sectors. Evaluating AI Return on Investment: Results from tech titans Microsoft and Meta Platforms dictate the broader tone for the Nasdaq. Analysts are scrutinizing rising data center capital expenditure budgets to determine if massive AI infrastructure investments are successfully translating to matching top-line growth. Bracing for the Apple Milestone: The technology market is focused on Apple's earnings report scheduled after the close. Options pricing indicates a projected 4% swing for the stock, which has hovered around a historic $5 trillion market capitalization under incoming leadership. Reviewing the Corporate Earnings Slate: Beyond mega-cap tech, Thursday's corporate earnings docket includes vital health, financial, and industrial indicators from companies such as Mastercard, Regeneron Pharmaceuticals, and Valero Energy. 📈Trade Idea: I’m going to focus on SPY calls and puts due to everything that’s going on. I’m talking about short-term hold times, trading at-the-money options that expire very soon. I will use VWAP as my primary buy/sell indicator, and I’ll also pay attention to the 3 and 8 exponential moving averages. I’ll primarily use a 5-minute chart with extended hours turned on. If you have no idea what I’m talking about, this is actually pretty basic trading lingo, and it’s not difficult to process once you learn it. Rather, stuff like this becomes second nature. Olivia Voz is a SPY trading legend, and you can learn from her top strategies right now. Go here. You’ll get the SPY ins and outs you need to know right away. You’ll be gifted a new free report just for checking it out! I hope you have a great day, enjoy the highly valuable resources provided in this message, and successfully move money out of the market into your pocket today! To YOUR Success, Questions or concerns about our products? Contact support@ragingbull.com /  1-800-380-7072 DISCLAIMER: This entity is owned by RagingBull LLC (RB). Full disclaimer https://ragingbull.com/disclaimer/. We are a financial publisher, not a registered investment advisor. Our content is for informational purposes only and should not be considered personalized investment advice. All trading involves substantial risk of loss and you may lose some or all of your invested capital. Past performance does not guarantee future results. *PAID PROMOTION: The content above is a paid promotion. RB receives compensation from the company or affiliate partners featured in this email. We are paid to distribute this content and have a financial interest in promoting these products or services. RagingBull is not responsible for any content hosted on third-party sites or your experience with third-party advertisers. It is the third party's responsibility to ensure compliance with applicable laws. We may hold positions in securities we discuss and may trade without notice. We make no guarantees or warranties about what is advertised and have no fiduciary duty to subscribers. Always consult a qualified financial professional before making investment decisions.   Update your email preferences or unsubscribe here © 2026 The Coin Insider 62 Calef Hwy. #233 Lee, NH 03861, United States Terms of Service

Low Float (Nasdaq: IMNN) Claims Our #1 Watchlist Spot With 6 Potential Catalysts

Our latest profile was on fire right out of the gate.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Low Float (Nasdaq: IMNN) Claims Our #1 Watchlist Spot With 6 Potential Catalysts July 30th Dear Reader, Our latest profile was on fire right out of the gate. After it closed at $5.80 on Tuesday, it climbed to a Wednesday high of $7.55. That rapid move translated into a surge of approximately 30%. Now consider the following… For three decades, the standard treatment approach for newly diagnosed advanced ovarian cancer has gone virtually unchanged. That's not just a gap in innovation. That's a wall. And Imunon, Inc. (Nasdaq: IMNN) looks like it may be punching through. IMNN is a clinical-stage biopharmaceutical company with one driving mission: bringing a first-in-class DNA-based immunotherapy to bear on one of oncology's most stubborn cancers. The company's approach doesn't follow the conventional playbook of adding another layer of chemotherapy to an already burdened treatment regimen. Instead, it takes a fundamentally different biological route — one designed to mobilize the patient's own immune defenses against the tumor. The foundation of that route is the TheraPlas® nanoparticle platform, a proprietary gene delivery system that carries therapeutic DNA straight to the tumor site without relying on a viral vector. The lead asset, IMNN-001, uses this platform to express interleukin-12 (IL-12), a powerful immune-activating cytokine, directly within the abdominal cavity where ovarian tumors typically take hold. Earlier IL-12 therapies hit a wall because systemic delivery triggered severe toxicities. IMNN-001 solves that through localized delivery and a safety record that Phase 2 data backs up. In a randomized 112-patient OVATION 2 study, IMNN-001 extended median overall survival by 14.7 months over standard-of-care chemotherapy alone, 45.1 months versus 30.4 months in the control group. For the subgroup that also received PARP inhibitor maintenance therapy, that advantage grew to 24.2 months. The OVATION 2 findings were subsequently published in the peer-reviewed journal Gynecologic Oncology and earned an oral presentation slot at the 2025 ASCO Annual Meeting — one of oncology's most coveted scientific stages. The company has since advanced to Phase 3. The OVATION-3 trial is a 500-patient, randomized registrational study with overall survival as the primary endpoint. In June 2026, the independent Data Monitoring Committee completed a planned interim safety and efficacy review and recommended the trial continue without modification. That is a critical clinical milestone, confirming the program is progressing as designed and that no safety concerns have surfaced. Most recently, on July 23rd, 2026, Imunon presented new IMNN-001 data at the inaugural AACR Conference on Drug Discovery and Development in Boston. Imunon CEO, Stacy Lindborg, called the selection "an important recognition of Imunon's platform," and Chief Medical Officer Sebastien Hazard said the program "establishes a new paradigm for immunotherapy" in this indication. Taking a Closer Look: Imunon, Inc. (Nasdaq: IMNN) Imunon emerged from the former clinical-stage company Celsion Corporation, which rebranded in 2022 to signal its sharpened focus on DNA-based immunotherapy. Central to that focus is the proprietary TheraPlas® platform, a non-viral, nanoparticle delivery system engineered to transport therapeutic DNA into the tumor microenvironment, sidestepping both the manufacturing complexity and immunogenic risks that come with viral vector approaches. IMNN-001 is a DNA plasmid encoding interleukin-12 (IL-12), a powerful immune-activating cytokine, delivered directly into the abdominal cavity (intraperitoneally). Prior attempts to leverage IL-12 systemically fell short because the doses required for therapeutic benefit produced severe toxicity. Imunon's method circumvents that entirely. By delivering IL-12 locally via TheraPlas®, the treatment activates immune response at the tumor site — flipping an immunologically "cold" tumor into an active, immune-engaged environment, while minimizing exposure throughout the rest of the body. In OVATION 2, no serious immune-related adverse events were recorded. The pipeline reaches well beyond ovarian cancer. The same TheraPlas® platform is being explored in colorectal cancer, pancreatic cancer, and glioblastoma. IMNN-001 holds FDA Fast Track designation and Orphan Drug designation in both the United States and the European Union, a regulatory package that may help support an accelerated path toward a potential BLA submission. The Company's Must-See Product Pipeline 6 Potential Catalysts That Could Make (Nasdaq: IMNN) Worth Watching #1. Phase 3 OVATION-3 Enrollment Is Running Ahead Of Projections: IMNN's clinical momentum has beaten initial expectations, with enrollment tracking ahead of schedule and 50% enrollment now targeted for Q1 2028, per the company's Q1 2026 update. #2. Data Safety Committee Greenlit The Trial In June: The independent Data Monitoring Committee reviewed OVATION-3 in June 2026 and recommended the study continue without changes, a major regulatory checkpoint confirming the integrity of the trial's safety profile and design. #3. FDA Protocol Alignment Strips Away Key Regulatory Risk: The FDA has confirmed alignment with IMNN on the OVATION-3 protocol and the pathway to BLA filing, a pivotal regulatory achievement that substantially reduces uncertainty around the approval process. #4. Analyst's $25 Price Target Implies Potential Quadruple-Digit Upside: A research analyst at Zacks Small Cap Research has set a $25 price target on IMNN. Measured from Wednesday's close, that target implies a potential 1,400%+ upside. #5. A Tight Float Could Create A Potential Environment For Heightened Volatility: With an estimated float of roughly 3.81Mn shares, the conditions for heightened volatility may be firmly in place. #6. AACR Conference Presentation Adds Scientific Credibility: Imunon was invited to present IMNN data at the inaugural AACR Conference on Drug Discovery and Development in Boston on July 23rd, 2026, providing additional peer-level scientific validation for the TheraPlas® platform and its clinical outcomes. Final Take Imunon, Inc. (Nasdaq: IMNN) is a clinical-stage company carrying a development story that's hard to ignore. Three decades without a meaningful step forward in frontline ovarian cancer treatment is the type of stagnation that marks entire careers in medicine, and one that could define a company's legacy if they're the one to change it. We're launching coverage on Imunon, Inc. (Nasdaq: IMNN). Watch for updates coming soon. More to follow shortly. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

Fierce Investor | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice

Sitting Below $1 (NYSE American: VNRX) Leads Our Watchlist This Morning With Less Than 7M Shares Available To The Public Right Now

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Market Crux Just Put VolitionRx Limited (NYSE: VNRX) On This Morning’s Watchlist—Thursday, July 30, 2026 Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Pull Up VNRX While It’s Still Early… July 30, 2026 Dear Reader, Two companies. One agreement. Very different sizes. The first has been building diagnostics equipment since 1968. Its analyzers run in hospital labs across more than 190 countries and regions. That is Sysmex Corporation. The second is worth about $7Mn and employs 67 people. That is VolitionRx Limited (NYSE American: VNRX). On June 17, 2026, they signed a collaboration agreement. Read that again. The manufacturer selling into 190 countries signed with the 67-person company. Agreements rarely run in that direction, and Sysmex has its pick of partners. So why this one? Because its own engineers had already put Volition's Nu.Q NETs H3.1 assay onto the Sysmex platform and watched it hold up. The commitment followed the result, not a pitch. The two are optimizing it together now. Volition's entire plan is to license its tests to partners who already own the machines and the hospital relationships. Before June 17, that plan lived on a slide. And here is what most of the market has not caught up to yet. There is a $5Mn contractual payment waiting on a study already sitting with peer reviewers. That single payment is worth more than the entire company at current levels. That is why (VNRX) leads our report this morning. The bell is about 90 minutes out, and there is more below. But keep in mind, (VNRX) has fewer than 7M shares listed as available to the public. That is a small number. When floats get this tight, the potential exists for big swings once demand shifts. Now look at where it sits. (VNRX) is currently below $1 and drawing little attention. That combination has pushed the near-term momentum readings into rare territory. Barchart shows the Relative Strength Index on (VNRX) at 15.49 on a 9-day basis. 21.92 on 14-day. 26.61 on 20-day. Anything under 30 is what most technical readers call oversold. Some frameworks tie readings like these to the setup for a potential trend reversal. Several Analysts Have Taken Notice Maxim Group analyst Michael Okunewitch has a bullish rating on VNRX with a $4 target. And according to TipRanks, Justin Walsh at Jones raised his target on VNRX from $3 to $24, which suggests significant upside potential from its recent range. Revenue is moving too. Volition reported first-quarter 2026 revenue near $1Mn. That is a 300% increase over the same period last year. And Sysmex was not the only signed development to land here this summer. On July 7, 2026, Volition released real-world data on its Nu.Q Cancer assay. The work showed prognostic value in newly diagnosed lung cancer patients. It was produced alongside clinicians at Hospices Civils de Lyon. See full story here. Clinical certification at that hospital system is already complete. A reimbursement submission in France is being prepared, with routine clinical use targeted before year end. That is the surface. Here is the foundation underneath it. What VNRX Actually Does VolitionRx Limited builds blood tests. That is the simple version. The longer one: it is a multi-national epigenetics company developing blood-based tests to detect and monitor cancer, plus diseases tied to NETosis, including sepsis. Research and development runs out of Belgium. There is an innovation lab and office in the United States, and an office in London. Headquarters sit in Henderson, Nevada. Roughly 67 people work there. Now here is the part that matters. Everything this company sells comes off one proprietary platform. It is called Nucleosomics. It measures nucleosomes and their epigenetic modifications as they circulate in your blood. From that single core, Volition built four separate commercial pillars. Four clinical problems. One research engine behind all of them. Pillar one is the furthest along. Nu.Q Vet already sells in more than 20 countries. The canine cancer test is live and generating revenue today. A feline version is next. It targets lymphoma, the most common cancer in cats. Volition submitted it for peer review after the assay detected 86% of feline lymphomas at 97% specificity. See full story here. Publication is expected to unlock a $5Mn contractual milestone payment. Management also believes a feline test could roughly double what it can address in companion animal health. Pillar two is already in hospitals. Nu.Q NETs is CE-marked and clinically available across Europe. The market behind it runs an estimated $3.8Bn. Pillar three is close. Nu.Q Cancer is moving toward routine clinical use in lung cancer in France. Pillar four is the largest. Capture-Seq is the earliest-stage program, a liquid biopsy method the company estimates addresses roughly $23Bn a year. So where does the money come from today? Four places. Assay sales. Research services through Nu.Q Discover. Contractual milestone payments. And non-dilutive funding from Walloon Region agencies in Belgium. But licensing is where management expects the step change. Upfront payments. Milestones. Royalties from large diagnostics groups. And those conversations are already happening. The company has confirmed active discussions with more than a dozen of the world's leading diagnostics and liquid biopsy companies. Several are at the technical evaluation stage already. VNRX Is Aiming At $27Bn With 67 Employees Liquid biopsy is one of the few corners of diagnostics where clinical need and reimbursement are moving at the same time. The economics are simple. A blood draw that catches disease earlier costs a fraction of the imaging, biopsy, and late-stage treatment it replaces. So what has held the field back? Not the science. The cost. Sequencing-based approaches stay expensive enough that broad screening is hard to justify outside high-risk groups. Volition sits in that sector differently, in two ways. First, it is platform-based, not indication-based. Most companies this size build one test for one disease. One regulatory path. One point of failure. Volition's nucleosome chemistry covers cancer detection, sepsis triage, chronic inflammatory disease, and veterinary oncology off the same science. Several paths forward. One research budget. Second, it stays capital-light commercially. The company estimates combined addressable markets above $27Bn across its pillars. The sepsis side deserves its own look. Published estimates put global sepsis cases near 166M a year. Sepsis-related deaths accounted for 31.5% of all global deaths in 2021. Volition's Nu.Q NETs assay is already inside DETECSEPS, a government-backed program in France worth roughly $7.3Mn. It starts in the third quarter of 2026. What Landed At VNRX While Nobody Was Looking July 7, 2026 Lung Cancer Data Lands With France's Second Largest Hospital System Volition released clinical data showing the prognostic value of its Nu.Q Cancer assay in newly diagnosed lung cancer patients. The work was produced with researchers at Hospices Civils de Lyon. Clinical certification at HCL is already complete. A reimbursement submission in France is being prepared. See full story here. June 17, 2026 A Global Diagnostics Manufacturer Signs On Volition announced its collaboration with Sysmex (TYO: 6869) to optimize the Nu.Q NETs H3.1 assay on the Sysmex platform. The agreement followed successful transfer of the assay onto that system. See full story here. June 3, 2026 New Patent Filing Extends Nu.Q NETs Into Outbreak Settings Volition filed a new patent application covering use of its Nu.Q NETs test for triage and treatment monitoring in outbreak settings. The company stated it is seeking strategic partners to deploy the platform in affected regions. See full story here. May 27, 2026 One Update, Four Pillars, $27Bn In Addressable Markets A consolidated corporate update detailed 300% first quarter revenue growth. It also covered progress toward the $5Mn veterinary milestone, inclusion of Nu.Q NETs in the DETECSEPS program, and active licensing discussions with more than a dozen global diagnostics leaders. See full story here. May 6, 2026 A $5Mn Payment Now Sits With Peer Reviewers Volition submitted for peer review a clinical manuscript reporting the accuracy of its Nu.Q Vet feline prototype assay in detecting lymphoma in cats. Publication is expected to unlock a $5Mn contractual milestone payment. See full story here. April 29, 2026 From Hospital Lab To Finger Prick Volition reported successful detection of nucleosomes in capillary blood from critically ill sepsis patients using a lateral flow prototype. The finger-prick format could extend testing to the bedside, the emergency room, and eventually the home. See full story here. Why VNRX Has Our Full Focus This Morning —Thursday, July 30, 2026… 1. A Giant Signed: A diagnostics manufacturer selling in more than 190 countries put its name on an agreement with VNRX, which means the technology cleared a serious technical review first. 2. Tight Share Count: With fewer than 7M shares listed as available to the public, VNRX’s small float could have the potential to witness big swings if demand begins to shift. 3. News Keeps Coming: Six separate announcements have come out of (VNRX) in ten weeks, a heavy pace for a company this size. 4. Wide Target Spread: Analyst targets on VNRX run from $4 up to $24 according to TipRanks, and the lowest of them still sits above where it closed Monday. 5. Revenue Climbing: First-quarter revenue at VNRX reached roughly $1Mn, four times what the company recorded a year earlier. 6. Four Shots Total: One platform gives VNRX four separate programs, so a delay in any single area does not stall the rest. 7. Hospital Cleared It: A major French hospital system has finished certifying the cancer test from VNRX, and reimbursement paperwork is the next step. Pull Up VNRX While It’s Still Early… Market Crux looks for companies that have done more than the market has noticed. VNRX fits this mold. It has fewer than 7M shares available to the public. Its market value sits near $7Mn. It just signed an agreement with one of the largest blood test manufacturers in the world. Revenue is four times what it was a year ago. And a $5Mn payment is waiting on a study that is already with reviewers. That is why VNRX is topping our watchlist this morning. Take a look while it’s still early, and watch for my next update. Sincerely, Gary Silver Managing Editor, Market Crux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, MC is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 07/29/2026 and ending on 07/30/2026 to publicly disseminate information about (VNRX:US) via digital communications. Under this agreement, TD Media LLC has paid Headline Media LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Headline Media LLC has been paid twenty two thousand five hundred USD (“Funds”). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC and their member own shares of (VNRX:US). Please see important disclosure information here: https://marketcrux.com/disclosure/vnrx-TK2Ns/#details

Headline Media | 7901 4th Street N, Suite 300, St. Petersburg, FL 33702 Unsubscribe Update Profile | About our service provider Sent by gary@marketcrux.net